empagliflozin and linagliptin tablets
for oral use Initial U.S. Approval: 2015
Facts about empagliflozin and linagliptin tablets
Approval Date: 2015
Proprietary Name: GLYXAMBI (empagliflozin and linagliptin) tablets
Active Ingredient(s): empagliflozin and linagliptin
Dosage Form: Tablets: • 10 mg empagliflozin/5 mg linagliptin • 25 mg empagliflozin/5 mg linagliptin
Medicine Approved By: Food and Drug Administration (FDA)
Manufacturer: Boehringer Ingelheim Pharmaceuticals, Inc
Summary of FDA-approved use on approval date: Click Here
(see Drugs@FDA for complete indication)
Access the best support services globally
If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “empagliflozin and linagliptin tablets” based on the information you provide.
Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.
MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398
Query For empagliflozin and linagliptin tablets
Approved accessible "empagliflozin and linagliptin tablets"
GLYXAMBI is a prescription medicine that contains 2 diabetes medicines, empagliflozin (JARDIANCE) and linagliptin (TRADJENTA). GLYXAMBI can be used: o along with diet and exercise to lower blood sugar in adults with type 2 diabetes, o in adults with type 2 diabetes who have known cardiovascular disease when both empagliflozin (JARDIANCE) and linagliptin (TRADJENTA) is appropriate and empagliflozin (JARDIANCE) is needed to reduce the risk of cardiovascular death. • GLYXAMBI is not for people with type 1 diabetes. • GLYXAMBI is not for people with diabetic ketoacidosis (increased ketones in the blood or urine). • If you have had pancreatitis in the past, it is not known if you have a higher chance of getting pancreatitis while you take GLYXAMBI. It is not known if GLYXAMBI is safe and effective in children under 18 years of age.
Active ingredients: empagliflozin and linagliptin Inactive ingredients: mannitol, pregelatinized starch, corn starch, copovidone, crospovidone, talc and magnesium stearate. The film coating contains the following inactive ingredients: hypromellose, mannitol, talc, titanium dioxide, polyethylene glycol. 10 mg/5 mg tablets also contain yellow ferric oxide. 25 mg/5 mg tablets also contain red ferric oxide.
How To access empagliflozin and linagliptin tablets?
GLYXAMBI (empagliflozin and linagliptin) tablets for oral use Initial U.S. Approval: 2015
To access empagliflozin and linagliptin tablets sold under the brand name can be made available on request to patient if the drug has not been approved or is not available in your country. For information or advice, call IPN's Pharmaceutical Expert. Our expert will be happy to take your query and guide with an effective solution. Be free and call today for full support at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj)
Indian Pharma Network (IPN), New Delhi. India
Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa